Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combination with durvalumab as treatment in patients with unresectable locally advanced or metastatic BTC.

Trial Details

NCT ID
NCT05733598
Phase
PHASE2
Sponsor
Replimune, Inc.
Status
RECRUITING
Cancer Type
Hepatocellular Carcinoma (HCC) Liver Cancer
Interventions
  • RP2
  • Bevacizumab
  • Atezolizumab
  • Durvalumab
  • RP2 Monotherapy
Locations (sample)
  • Beverly Hills, California, United States|34.07362,-118.40036
  • La Jolla, California, United States|32.84727,-117.2742
  • Miami, Florida, United States|25.77427,-80.19366
  • Tampa, Florida, United States|27.94752,-82.45843
  • Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

  • I 1. Male or female ≥ 18 years of age. I 2. (HCC only) Has locally advanced unresectable, recurrent, and/or metastatic HCC, with the diagnosis conf…
  • I 3. (HCC only) Must have progressed while on first and only systemic therapy, which must have included anti PD-1 or anti-PD-L1 therapy (eg, atezol…
  • I 4. (HCC only) Child-Pugh A, determined within 14 days before first study treatment.
  • I 5. Has at least 1 measurable tumor of ≥ 1 cm in longest diameter (or ≥ 1.5 cm shortest diameter for lymph nodes) as defined by RECIST 1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hepatocellular Carcinoma (HCC) Liver Cancer Trials on Trialify →